Clinical Trial Update: A Study of Two Doses of Intravenous NATRECOR hBNP (Nesiritide) in Patients With Worsening Congestive Heart Failure Who Have Difficulty Breathing at Rest [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating two doses of intravenous nesiritide (NATRECOR) in patients with worsening congestive heart failure and dyspnea at rest.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• NATRECOR (nesiritide) (nesiritide)

Snippet

Sponsor: Scios, Inc. | Conditions: Heart Failure, Congestive, Heart Decompensation | Phase 3 | Status: COMPLETED